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Introduction: One of the three core principles of the EMCDDA  
2013–15 strategy is a commitment to efficiency. This is to be 
achieved, among others, via an improved quality assurance framework 
for the statistical procedures employed by the agency. In this light, an 
EMCDDA Internal statistics code of practice was developed in 2014. 
The code was drawn up in consultation with the EMCDDA Scientific 
Committee, the Reitox network and Eurostat, whose European 
statistics code of practice provided a basis for the work.
The EMCDDA code establishes a set of principles that provide the 
agency with guidance and objectives for its own work. It serves as 
a declaration of the EMCDDA’s intent to pursue a programme of 
continuous improvement and evaluation of efforts in order to provide 
‘factual, objective, reliable and comparable information’. 
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This document establishes a set of relevant principles that provide the EMCDDA with 
guidance and goals for its own work. It is a declaration of the EMCDDA’s intent to 
pursue a programme of continuous improvement and evaluation of efforts to provide 
‘factual, objective, reliable and comparable information’. It is not a description of current 
achievements, but rather the establishment of goals to be pursued. This code may also be a 
useful point of reference for the Reitox network.
In line with Eurostat’s European statistics code of practice, the EMCDDA Statistics code 
of practice is based on 15 principles covering the institutional environment, the statistical 
production processes and the output of statistics. A set of statements of good practice for 
each of the principles provides guidance for the implementation of the code (1).
I The objective of the EMCDDA 
The founding regulation of the EMCDDA defines that the objective of the EMCDDA is 
to provide ‘the Community and its Member States with factual, objective, reliable and 
comparable information at European level concerning drugs and drug addiction and their 
consequences’ (2), focusing on the following priority areas:
1) monitoring the state of the drugs problem, in particular using epidemiological or other indicators, 
and monitoring emerging trends, in particular those involving poly-drug use;
2) monitoring the solutions applied to drug-related problems; providing information on best practices in 
the Member States and facilitating the exchange of such practices among them;
3) assessing the risks of new psychoactive substances and maintaining a rapid information system 
with regard to their use and also regarding new methods of using existing psychoactive substances;
4) developing tools and instruments to help Member States to monitor and evaluate their national 
policies and the Commission to monitor and evaluate European Union policies. 
Regulation (EC) No 1920/2006
The founding regulation of the EMCDDA determines that ‘the statistical element (…) shall 
be developed, in collaboration with the relevant statistical authorities, using as necessary 
the Community Statistical Programme to promote synergy and avoid duplication’ (3). 
The EMCDDA strives to provide the users of its data with a level of integrity, service and 
commitment in the statistical collection and analysis process and in statistical outputs 
comparable to that of other EU data providers and statistical offices, while noting that the 
structure of the data collection and the nature of the topic influences the type and level of 
quality assurance that is appropriate. 
The EMCDDA is not a primary data collector. The EMCDDA works in close collaboration with 
(1) The quality criteria for European statistics are defined in Regulation (EC) 223/2009, Article 12. 
(2) Regulation (EC) No 1920/2006 of the European Parliament and of the Council of 12 December 2006 on the 
EMCDDA (recast).
(3) Article 1.3 of Regulation (EC) No 1920/2006 (see above).
.
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(4) Article 5 of Regulation (EC) No 1920/2006 (see above)
(5) See, in particular, the EMCDDA protocols for the five key epidemiological indicators (http://www.emcdda.europa.eu/
activities/key-indicators).
the European Information Network on Drugs and Drug Addiction (Reitox) (4) to compile 
aggregated data to provide information at an EU level. One Reitox national focal point in 
each Member State is responsible for the collection and analysis of data at national level 
on the basis of guidelines adopted with the EMCDDA.
National focal points have the responsibility for collecting and analysing data at national 
level, and rely for this on their network of national experts. They collaborate with the 
EMCDDA to improve the quality and harmonisation of data across the EU and to facilitate 
and structure the exchange of information (5).
Investigating the illicit drug phenomenon involves collecting and analysing information on 
hidden populations. Data can be partial and difficult to validate. The topic is complex, with 
determinants that are difficult to separate. Ensuring data quality is an on-going process 
that is continuously being developed.




Institutional and organisational factors influence an information agency’s effectiveness 
in the collection, analysis and dissemination of credible statistics. The relevant issues are 
professional independence, mandate for data collection, adequacy of resources, quality 
commitment, confidentiality, impartiality and objectivity.
I Principle 1 – Professional independence
Within the context of its mandate, the professional independence of the EMCDDA 
underpins the credibility of the statistics it produces. The work of the EMCDDA is carried 
out with due regard to the respective powers of the EU and its Member States in the area 
of drugs and is guided by the drugs strategies and action plans adopted by the European 
Union. The EMCDDA strives to ensure that its working methods are transparent and 
consistent.
Supporting statements:
1.1: The EMCDDA is a public and non-profit legal person created under EU law with a formal 
mandate to produce and disseminate statistics, as specified in the EMCDDA founding 
regulation. 
1.2: The EMCDDA relies on Reitox national focal points for ensuring the validity and 
reliability of data provided to the EMCDDA in the framework of the national reporting 
package.
1.3: The EMCDDA provides guidance and protocols, agreed with Reitox national focal points 
and national experts, for the data requested in the framework of the national reporting 
package. The EMCDDA is responsible for coordinating and harmonising the collection 
of that data and for producing and disseminating EU drugs statistics in an independent 
manner. 
1.4: The EMCDDA has the sole responsibility for deciding on the statistical methods, 
standards, procedures, content and timing of EMCDDA statistical outputs, seeking 
guidance, where appropriate.
1.5: The EMCDDA work programmes are published and the annual General Reports of 
Activities describe progress made. 
1.6: A clear distinction is made between statistical outputs that report data received from 
the Reitox national focal points and any statistics calculated on the basis of those data. 
Sources of data are clearly defined. 
1.7: The EMCDDA Scientific Committee, Management Board and the Reitox network are 
consulted on the EMCDDA’s main statistical outputs in advance of publication as part of 
the quality assurance process. 
I Principle 2 – Mandate for data collection
The EMCDDA and the Reitox network have a clear legal mandate to collect factual, 
objective, reliable and comparable information concerning ‘drugs and drug addiction and 
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their consequences’ (6). In addition, the EMCDDA, also has a role in the identification and 
assessment of the risks of new substances (7).
Supporting statements:
2.1: The founding regulation of the EMCDDA designates the EMCDDA as the hub for all 
drug-related information in the EU and provides the basis for the collection, analysis and 
dissemination of data on drugs and the consequences of drug use from the Member States 
and other countries.
2.2: National authorities ensure the operations of their Reitox national focal points for the 
collection and analysis of data at national level on the basis of guidance and protocols 
agreed with the EMCDDA.
2.3: The Reitox national focal points, the European Commission and the Member States 
are the main providers of data to the EMCDDA, as designated by its founding regulation. 
Complementary information emanating from the EU, non-governmental organisations 
and international organisations is collected, analysed and disseminated in line with the 
EMCDDA mandate. 
2.4: The EMCDDA strives to avoid duplication of work by liaising with other EU and 
international institutions and agencies. 
2.5: In line with its mandate and where appropriate, the EMCDDA will carry out surveys, 
preparatory studies and feasibility studies, together with any pilot projects necessary to 
accomplish its tasks.
I Principle 3 – Adequacy of resources
Within the constraints imposed on European and national budgets, sufficient resources 
should be made available to meet European drug-related statistics requirements.
Supporting statements:
3.1: EMCDDA and Reitox network staff, financial and computing resources should be 
adequate, both in magnitude and in quality, to meet current statistical needs. 
3.2: The scope, detail and cost of drug-related statistics should be commensurate with 
needs, as defined in the EMCDDA work programme. 
3.3: Procedures should be in place to periodically assess and justify the continued 
collection of existing statistics and demands for new statistics against their cost.
I Principle 4 – Commitment to quality
The EMCDDA and the Reitox network are committed to quality. The EMCDDA systematically 
and regularly identifies strengths and weaknesses by continuously monitoring process and 
product quality. 
(6) Regulation (EC) No 1920/2006 of the European Parliament and of the Council of 12 December 2006 on the 
EMCDDA (recast). 
(7) Council Decision 2005/387/JHA of 10 May 2005 on the information exchange, risk assessment and control of 
new psychoactive substances [Official Journal L 127, 20.5.2005].
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Supporting statements:
4.1: A quality policy is defined and made publicly available. An organisational structure and 
tools are in place to deal with quality management.
4.2: Procedures are in place to plan and monitor the quality of the statistical production 
process. 
4.3: The quality of EMCDDA key statistical outputs is regularly reviewed, using external 
experts where appropriate, and reported according to the established quality criteria.
I Principle 5 – Confidentiality
The EMCDDA does not disseminate any statistical data that would make possible the 
identification of individuals or small groups of individuals. The privacy of data providers, the 
confidentiality of the information they provide and its use only for statistical purposes are 
guaranteed.
Supporting statements:
5.1: Staff sign legal confidentiality commitments on appointment. 
5.2: Procedures are in place to deal with any breaches of confidentiality. 
5.3: Guidelines and instructions are provided to staff on the protection of confidentiality in 
the production and dissemination of statistics. The confidentiality policy is made known to 
the public. 
5.4: Where relevant, appropriate procedures are in place to protect the handling of 
classified data and information.
5.5: Physical, technological and organisational provisions are in place to protect the security 
and integrity of statistical databases. 
5.6: Protocols apply to external users accessing statistical data for research purposes.
I Principle 6 – Impartiality and objectivity
The EMCDDA collects, analyses and disseminates European drug-related statistics 
maintaining scientific independence and in an objective, professional and transparent 
manner. 
Supporting statements:
6.1: Statistics are compiled on an objective basis determined by statistical considerations. 
6.2: Choices of sources, statistical methods as well as decisions about the presentation and 
dissemination of statistics are informed by statistical considerations. 
6.3: Errors discovered in published statistics are corrected at the earliest possible date and 
appropriately publicised. 
6.4: Information on the methods and procedures used is publicly available. 
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6.5: Statistical publication dates and times are pre-announced. 
6.6: Advance notice is given to EMCDDA partners on major revisions or changes in 
methodologies. 
6.7: The EMCDDA collects secondary data. Data should be validated by Reitox national 
focal points before publication, where appropriate.
Statistical processes 
European and other international standards, guidelines and good practices are observed 
in the processes used by the EMCDDA to collect, analyse and disseminate European 
statistics. The credibility of the statistics is enhanced by a reputation for good management 
and efficiency. The relevant aspects are sound methodology, appropriate statistical 
procedures, non-excessive burden on data providers and cost-effectiveness. 
I Principle 7 – Sound methodology
Sound methodology underpins quality statistics. This requires adequate tools, procedures 
and expertise.
Supporting statements:
7.1: The overall methodological framework used for EMCDDA statistics follows European 
and other international standards, guidelines, and good practices. 
7.2: Procedures are in place to ensure that standard concepts, definitions and 
classifications are consistently applied throughout the EMCDDA. 
7.3: Procedures are in place to promote the harmonisation of national data collection 
following EMCDDA guidance and protocols. 
7.4: Graduates in the relevant academic disciplines are recruited. 
7.5: The EMCDDA has a training policy for its staff. 
7.6: Co-operation with the scientific community, and in particular with the EMCDDA 
Scientific Committee and national experts, is organised to improve methodology, the 
effectiveness of the methods implemented and to promote better tools when feasible. 
I Principle 8 – Appropriate statistical procedures
Appropriate statistical procedures are implemented from data collection to data validation. 
Sufficient information is collected on the methods of data collection from the data providers 
to allow for quality assessment. Efforts are made to share good statistical practices. 
Appropriate statistical procedures are followed within the EMCDDA.
Supporting statements:
8.1: Data providers and experts are consulted on the concepts, definitions and practices 
adopted at the time of data collection, and these are evaluated according to the statistical 
purpose of the data.
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8.2: Information is collected on data collection items, study designs, sample selection and 
estimation methods used at national level, and this information is evaluated.
8.3: Efforts are made to promote the design of administrative data in order to make them 
suitable for statistical purposes. This is achieved by reviewing the statistical needs at 
European level with the Reitox national focal points and experts.
8.4: EMCDDA data collection instruments are tested, reviewed and revised with the data 
providers.
8.5: Collection, entry and coding of data are routinely monitored, reviewed and revised as 
required. 
8.6: Appropriate editing and imputation methods are used and regularly reviewed, revised 
or updated as required. 
8.7: Revisions follow standard, well-established and transparent procedures.
I Principle 9 – Non-excessive burden on data providers
The EMCDDA will monitor the burden on data providers and strive to avoid duplication and 
to ensure requests are commensurate to need. 
Supporting statements:
9.1: The range and detail of EMCDDA demands is limited to what is necessary to achieve 
the objectives established in its work programmes.
9.2: The information sought from data providers is, as far as possible, limited to information 
readily available from national sources. 
9.3: The EMCDDA will avoid unnecessary duplication in its requests to data providers.
I Principle 10 – Cost-effectiveness
Resources are used effectively. 
Supporting statements:
10.1: Internal and independent external procedures are in place to monitor the EMCDDA’s 
use of resources.
10.2: The productivity potential of information and communications technology is being 
optimised for data collection, analysis and dissemination.
10.3: The EMCDDA promotes and implements standardised approaches to data collection, 
analysis and reporting that increase effectiveness and efficiency.
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Statistical output 
Available statistics meet users’ needs. Statistics comply with the European quality 
standards and serve the needs of European institutions, governments, research institutions, 
business concerns and the public generally. The important issues concern the extent to 
which the statistics are relevant, accurate and reliable, timely, coherent, comparable across 
regions and countries, and readily accessible by users.
I Principle 11 – Relevance
European statistics meet the needs of users. 
Supporting statements:
11.1: Processes are in place to consult users, monitor the relevance and utility of existing 
statistics in meeting their needs, and consider their emerging needs and priorities. 
11.2: Priority needs are being met and reflected in the work programme. 
11.3: User satisfaction is monitored on a regular basis and is systematically followed up.
I Principle 12 – Accuracy and reliability
EMCDDA statistical outputs accurately and reliably portray reality.
Supporting statements:
12.1: Source data, intermediate results and statistical outputs are regularly assessed and 
validated.
12.2: Measures of statistical quality are collected, systematically documented and 
evaluated, according to European standards. 
12.3: The national reporting package is regularly analysed in order to improve statistical 
processes.
I Principle 13 – Punctuality/timeliness
EMCDDA statistical outputs are released in a timely and punctual manner. 
Supporting statements:
13.1: The EMCDDA strives to minimise the length of time between receiving data from data 
providers and disseminating those data. 
13.2: Efforts are made to co-ordinate data collection with data providers to ensure the 
earliest possible delivery to the EMCDDA.
13.3: Efforts are made to promote the production and delivery of recent national data from 
the data providers.
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EMCDDA, your reference point on drugs in Europe  
The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
is the hub of drug-related information in Europe. Its mission? To provide  
the EU and its Member States with an evidence base on the European 
drugs problem to inform policymaking and practice.
Contact us 
Praça Europa 1, Cais do Sodré, 1249-289 Lisbon, Portugal 
Tel. (351) 211 21 02 00 I Fax (351) 218 13 17 11 
info@emcdda.europa.eu I emcdda.europa.eu 
twitter.com/emcdda I facebook.com/emcdda
I Principle 14 – Coherence and comparability
EMCDDA statistical outputs are consistent internally, over time and comparable between 
regions and countries; it is possible to combine and make joint use of related data from 
different sources. 
Supporting statements:
14.1: Statistics are assessed for internal coherence and consistency (i.e. arithmetic and 
accounting identities observed) and corrected within the EMCDDA’s ability. 
14.2: The comparability of statistics over time is assessed and clearly documented.
14.3: Statistics are compiled on the basis of common standards with respect to scope, 
definitions, units and classifications defined in the relevant protocols. 
14.4: Statistics from different sources and of different periodicity are compared and 
reconciled. 
14.5: Cross-national comparability of the data is promoted by the EMCDDA by reference to 
agreed guidance and protocols and through periodic exchanges with its data providers.
I Principle 15 – Accessibility and clarity
EMCDDA statistical outputs are presented in a clear and understandable form, released 
in a suitable and convenient manner, available and accessible on an impartial basis with 
supporting metadata and guidance.  
Supporting statements:
15.1: Statistics and the corresponding metadata are presented and archived in a form that 
facilitates proper interpretation and meaningful comparisons. 
15.2: Dissemination services use modern information and communication technology and, 
if appropriate, traditional hard copy. 
15.3: Users are kept informed about the methodology of statistical processes in a 
standardised format.
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